

FIG 1




FIG 2




FIG 3




FIG 4











FIG 5A




BRI6796




BRI6797



BRI6798




BRI6799




BRI6800


FIG 5B




BRI6801




BRI6802



BRIX114




BRI6803




BRI6814


FIG 5C




BRI6815




BRI6816



BRI6817




BRI6822




BRI6823


FIG 5D




BRI6824




BRI6825



BRI6829




BRI6855




BRI6856


FIG 5E




BRI6857




BRI6864



BRI6865




BRI6868




BRI7001 R = NH₂
BRI7002 R = NH₃Cl

FIG 5F




BRI7009



BRI7012

FIG 5G


Inhibition or enhancement of Fc γ RIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 6


Inhibition or enhancement of Fc γ RIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


Inhibition or enhancement of Fc γ RIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

Inhibition or enhancement of Fc_YRIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9




FIG 10

• Inhibition of sFc γ RIa binding






FIG. 11



Activation of platelets in the presence of agonist only.
Platelets ($100 \times 10^6/\text{ml}$) were mixed in the presence of Fc γ RIIa agonist (HAGG, 200 $\mu\text{g}/\text{ml}$) and PBS and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 12



Activation of platelets in the presence of agonist and BRI compound 6855.
Platelets ($100 \times 10^6/\text{ml}$) were mixed in the presence of Fc_γIIa agonist (HAGG, 200 $\mu\text{g}/\text{ml}$) and compound BRI 6855 (5mg/ml) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

Effect of BRI compound 6728 on platelet aggregation with HAGG




FIG 14